Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PVRL2 suppresses anti-tumor immunity through PVRIG- and TIGIT-independent pathways

ABSTRACT: Here, we share discovery proteomics data associated with a larger study to expose new immunoregulatory mechanisms in cancer. PVRL2 was identified in both tumor cells and exosomes, and the role of this surface protein in the immune response to cancer was explored in further studies.

INSTRUMENT(S): Q Exactive Plus

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Primary Cell, Cell Culture

SUBMITTER: James Byrnes

LAB HEAD: James Wells

PROVIDER: PXD044245 | Pride | 2024-05-21

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	200723_TRAMP_200ng_JRB_Slot1-25_1_139.d.7z	Other
	200917_TRAMP_EXO_200ng_Slot2-33_1_331.d.7z	Other
	200917_TRAMP_INF_EXO_1_200ng_Slot2-31_1_329.d.7z	Other
	200917_TRAMP_INF_EXO_2_200ng_Slot2-32_1_330.d.7z	Other
	Data_Legend.xlsx	Xlsx

Items per page:

1 - 5 of 27

Publications

PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways.

Yang Jiuling J Wang Li L Byrnes James R JR Kirkemo Lisa L LL Driks Hannah H Belair Cassandra D CD Aguilar Oscar A OA Lanier Lewis L LL Wells James A JA Fong Lawrence L Blelloch Robert R

Cancer immunology research 20240501 5

Poliovirus receptor-related 2 (PVRL2, also known as nectin-2 or CD112) is believed to act as an immune checkpoint protein in cancer; however, most insight into its role is inferred from studies on its known receptor, poliovirus receptor (PVR)-related immunoglobulin domain protein (PVRIG, also known as CD112R). Here, we study PVRL2 itself. PVRL2 levels were found to be high in tumor cells and tumor-derived exosomes. Deletion of PVRL2 in multiple syngeneic mouse models of cancer showed a dramatic ...[more]

PMID: 38588410

Similar Datasets

Human Skin CD141+ Dendritic Cells Regulate Cutaneous Immunity via the Neuropeptide Urocortin-2

Project description:Skin immune homeostasis is a multi-faceted process where dermal dendritic cells (DDCs) are key in orchestrating responses to environmental stressors. We have previously identified CD141+CD14+DDCs as a skin-resident immunoregulatory population that is vitamin-D3(VitD3) inducible from monocyte-derived DCs(moDCs), termed CD141hiVitD3 moDCs. We demonstrate CD141+DDCs and CD141hiVitD3 moDCs share key immunological features including cell surface markers, reduced T-cell stimulation, IL-10 production, and a common transcriptomic signature. Bioinformatic analysis identified the neuroactive ligand receptor pathway and the neuropeptide, urocortin-2(UCN2), as a potential immunoregulatory candidate molecule. Incubation with VitD3 up-regulated UCN2 in CD141+DCs and ultraviolet-B(UVB) irradiation induced UCN2 in CD141+DCs in healthy skin in vivo. Notably, CD141+DDC generation of suppressive Tregs was dependent upon the UCN2 pathway as in vivo administration of UCN2 reversed skin inflammation in humanized mice. We propose the neuropeptide UCN2 as a novel skin DC- derived immunoregulatory mediator with a potential role in UVB and VitD3 dependent skin immune homeostasis.

2023-10-31 | GSE243690 | GEO

PRMT1 suppresses anti-tumor immunity

Project description:PRMT1 is known as a regulator of immune function by directly interacting with interferon receptors, methylating STAT1, and promoting B cell and macrophage differentiation by methylating CDK4 or B cell antigen receptor However, the function of PRMT1 as a therapeutic target of cancer remains largely elusive, particularly for its role in cancer immunosurveillance. Here, we performed bulk RNA-seq for CT26, a mouse tumor cell line, after either knocking down of endogeneous Prmt1 or blocking PRMT1 by two specific inhibitors, namely MS023 and GSK3368715.

2023-03-21 | GSE203466 | GEO

Megakaryocyte derived immunoregulatory cells regulate host-defense immunity against bacterial pathogens

Project description:Here, using single-cell sequencing we identified an MK derived immunoregulatory cell population, which plays an important role in host-protective responses against bacteria. In contrast to platelet-generating MKs, MK derived immunoregulatory cells highly express immune response genes and chemokines.

2022-03-24 | GSE168224 | GEO

FOXA1 suppresses cancer immunity independent of DNA binding

Project description:Exclusion of lymphocytes from tumors is a major barrier for effective immuno- and chemo-therapy of cancer. We found that FOXA1 overexpression inversely correlates with expression of antigen processing and presentation and interferon signaling genes in different cancer types. FOXA1 binds to STAT proteins and inhibits expression of antigen presentation and interferon response genes and tumor immunity independent of the forkhead domain - DNA binding function. Increased FOXA1 also correlates with immunotherapy resistance in murine triple negative breast tumor and bladder cancer in patients and chemo-resistance in breast cancer patients. Our results reveal that FOXA1 is a key immune suppressor, suggesting that FOXA1 overexpression may predict tumor resistance to immuno- and chemo-therapies and that depletion of FOXA1 may therapeutically convert cancers from ‘immune-cold’ to ‘immune-hot’ diseases.

2020-12-31 | GSE142221 | GEO

Transforming Growth Factor-b Suppresses Type 2 Immunity to Cancer

Project description:The immune system employs two distinct defense strategies against infections: pathogen elimination typified by type 1 immunity, and pathogen containment exemplified by type 2 immunity concomitant with tissue repair. Akin to infectious diseases, cancer progresses with cancer cell acquisition of microorganism-like behavior propagating at the expense of the host. While immunological mechanisms of cancer cell elimination are well defined, whether immune-mediated cancer cell containment can be induced is poorly understood. Here we show that ablation of transforming growth factor-β receptor II (TGFβRII) in CD4+ T cells promotes tumor tissue healing and halts cancer progression. The restorative response is associated with remodeling of the blood vasculature patterning with cancer cell hypoxia and death instigated in avascular regions, a process dependent on the T helper 2 cytokine IL-4. Thus, type 2 immunity represents an effective cancer defense mechanism, and TGFβ signaling in helper T cells may be targeted for tissue-level cancer immunotherapy.

2020-05-29 | GSE151406 | GEO

SETDB1-TRIM28 complex suppresses antitumor immunity [RNA-seq]

Project description:Epigenetic mechanism contributes to immune landscapes in cancer. Here we identify the SETDB1-TRIM28 complex as a critical suppressor of antitumor immunity. An epigenetic CRISPR-Cas9 screen of 1,218 chromatin regulators identified TRIM28 as a novel suppressor of PD-L1 expression. We revealed that expression of the SETDB1-TRIM28 complex negatively correlates with infiltration of effector CD8+ T cells. Inhibition of SETDB1-TRIM28 simultaneously upregulates PD-L1 and activates the cGAS-STING innate immune response to increase infiltration of CD8+ T cells. Mechanistically, SETDB1-TRIM28 inhibition leads to micronuclei formation in cytoplasm, a known activator of the cGAS-STING pathway. Thus, SETDB1-TRIM28 inhibition bridges the innate and adaptive immunity. Indeed, SETDB1 knockout enhances the antitumor effects of immune checkpoint blockade anti-PD-L1 in an ovarian cancer mouse model in a cGAS dependent manner. Our findings establish SETDB1-TRIM28 complex as a regulator of antitumor immunity and its loss activates cGAS-STING innate immunity to boost antitumor effects of immune checkpoint blockades.

2021-10-20 | GSE182089 | GEO

FOXA1 suppresses cancer immunity independent of DNA binding

Project description:FOXA1 suppresses cancer immunity independent of DNA binding

| PRJNA596242 | ENA

Dnase1l3 enhances antitumor immunity and suppresses tumor progression [scRNAseq]

Project description:For the chronic inflammation-related colon cancer model (AOM/DSS-colon cancer model), 3-month-old Dnase1l3 WT and KO mice were injected with AOM (8 mg/kg, body weight). One week later, mice were challenged with 2.5% DSS water for 7 days followed by a 14-day recovery with regular drinking water for three cycles. Body weight, rectal bleeding and diarrhea were monitored during the entire experiment. Mice with more than 25% weight loss were removed during the experiment. For the AOM model, 2-month-old Dnase1l3 WT and KO mice were injected intraperitoneally with AOM (8 mg/kg, body weight). Colon tissues were isolated 9 hours, or five days after injection. All animal experiments were conducted in accordance with guidelines of NIEHS/NIH Animal Care and Use Committee.

2022-02-07 | GSE196054 | GEO

SETDB1-TRIM28 complex suppresses antitumor immunity [CRISPR/Cas9 screen]

2021-10-20 | GSE182197 | GEO

The Gustatory Sensory G-Protein GNAT3 Suppresses Pancreatic Cancer Progression in Mice

Project description:Ablation of the gustatory G-protein, GNAT3, in damage and KRAS G12D induced pancreatic transformation enhanced CXCL1 and CXCL2 expression, altered the immunoregulatory gene expression of CXCR2 expressing myeloid-derived suppressor cells, and increased gMDSC presence to promote the progression of metastatic pancreatic ductal adenocarcinoma.

2021-04-21 | GSE149165 | GEO